Results 201 to 210 of about 22,026 (263)

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.

JAMA Netw Open
Hsiao FC, Hsu TJ, Hsieh YJ, Tung YC, Chen DY, Lin CP, Chen SW, Chu PH.   +7 more
europepmc   +1 more source

Heterogeneous effect of saxagliptin on glucose fluctuation and β-cell function in T1DM: a multicentre, randomised trial. [PDF]

Nutr Diabetes
Shi Y, Shen M, Gu Y, Chen Y, Xu K, Hu J, Fang C, Guo H, Xu N, Wang G, Lu W, Tao S, Zhao S, Fang C, Ma J, Yan R, Sun R, Qian L, Wu C, Jiang H, Yang T.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
Amides derived from fluorinated pyrrolidines and 4-substituted cyclohexylglycine analogues have been prepared and evaluated as inhibitors of dipeptidyl dipeptidase IV (DP-IV). Analogues which incorporated (S)-3-fluoropyrrolidine showed good selectivity for DP-IV over quiescent cell proline dipeptidase (QPP).
Charles G, Caldwell, Ping, Chen, Jiafang, He, Emma R, Parmee, Barbara, Leiting, Frank, Marsilio, Reshma A, Patel, Joseph K, Wu, George J, Eiermann, Aleksandr, Petrov, Huaibing, He, Kathryn A, Lyons, Nancy A, Thornberry, Ann E, Weber   +13 more
openaire   +3 more sources

Recent patents of dipeptidyl peptidase IV inhibitors

Expert Opinion on Therapeutic Patents, 2011
The serine exopeptidase DPP IV is a dual protein able to work as an enzyme and an interacting protein. The incretin molecules glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are hydrolyzed by DPP IV into inactive forms, which are unable to promote insulin secretion.
Laura, Mendieta, Teresa, Tarrago, Ernest, Giralt   +2 more
openaire   +2 more sources

Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)

Current Topics in Medicinal Chemistry, 2007
The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines.
Dana, Ferraris, Sergei, Belyakov, Weixing, Li, Eddie, Oliver, Yao-Sen, Ko, David, Calvin, Susan, Lautar, Bert, Thomas, Camilo, Rojas   +8 more
openaire   +2 more sources

Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2005
Dipeptidyl peptidase IV (DPP4) is a multifunctional type II transmembrane serine peptidase which regulates various physiological processes, most notably plasma glucose homeostasis by cleaving peptide hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Guohua, Zhao, Prakash C, Taunk, David R, Magnin, Ligaya M, Simpkins, Jeffrey A, Robl, Aiying, Wang, James G, Robertson, Jovita, Marcinkeviciene, Doree F, Sitkoff, Rex A, Parker, Mark S, Kirby, Lawrence G, Hamann   +11 more
openaire   +3 more sources

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2007
The synthesis and structure-activity relationships of novel dipeptidyl peptidase IV inhibitors replacing the classical cyanopyrrolidine P1 group with other small nitrogen heterocycles are described. A unique potency enhancement was achieved with beta-branched natural and unnatural amino acids, particularly adamantylglycines, linked to a (2S,3R)-2,3 ...
Ligaya M, Simpkins, Scott, Bolton, Zulan, Pi, James C, Sutton, Chet, Kwon, Guohua, Zhao, David R, Magnin, David J, Augeri, Timur, Gungor, David P, Rotella, Zhong, Sun, Yajun, Liu, William S, Slusarchyk, Jovita, Marcinkeviciene, James G, Robertson, Aiying, Wang, Jeffrey A, Robl, Karnail S, Atwal, Robert L, Zahler, Rex A, Parker, Mark S, Kirby, Lawrence G, Hamann   +21 more
openaire   +2 more sources

Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2009
A new series of DPP-4 inhibitors derived from piperidine-fused benzimidazoles and imidazopyridines is described. Optimization of this class of DPP-4 inhibitors led to the discovery of imidazopyridine 34. The potency, selectivity, cross-species DMPK profiles, and in vivo efficacy of 34 is reported.
Scott D, Edmondson, Anthony, Mastracchio, Jason M, Cox, George J, Eiermann, Huaibing, He, Kathryn A, Lyons, Reshma A, Patel, Sangita B, Patel, Aleksandr, Petrov, Giovanna, Scapin, Joseph K, Wu, Shiyao, Xu, Bing, Zhu, Nancy A, Thornberry, Ranabir Sinha, Roy, Ann E, Weber   +15 more
openaire   +2 more sources

Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis

Dermatology, 2011
A patient with a 17-year history of plaque psoriasis accompanied by type 2 diabetes mellitus discontinued cyclosporine and steroid ointment given for treatment of psoriasis because she was dissatisfied with the effects of the drugs. After sitagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, was administered for control of blood glucose, psoriatic
Tatsuya, Nishioka, Masayuki, Shinohara, Noriyasu, Tanimoto, Chizuru, Kumagai, Kozo, Hashimoto   +4 more
openaire   +2 more sources

A potent dipeptide inhibitor of dipeptidyl peptidase IV

Bioorganic & Medicinal Chemistry Letters, 1998
A series of novel potent inhibitors of dipeptidyl peptidase IV (DPP-IV) has been developed. A brief structure-activity relationship of the inhibitors was investigated. The dipeptide TSL-225, tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, was identified with the critical structure for the inhibitory activity.
M, Yamada, C, Okagaki, T, Higashijima, S, Tanaka, T, Ohnuki, T, Sugita   +5 more
openaire   +2 more sources